Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
IPO Year: 2019
Exchange: NASDAQ
Website: brainsway.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2023 | Outperform → Mkt Perform | Raymond James | |
| 3/3/2022 | $15.00 | Buy | Loop Capital |
| 11/29/2021 | $14.00 → $15.00 | Buy | HC Wainwright & Co. |
| 8/12/2021 | $17.00 → $14.00 | Buy | HC Wainwright & Co. |
| 7/19/2021 | $17.00 | Buy | HC Wainwright & Co. |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
3 - Brainsway Ltd. (0001505065) (Issuer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
SCHEDULE 13G - Brainsway Ltd. (0001505065) (Subject)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
6-K - Brainsway Ltd. (0001505065) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Raymond James downgraded Brainsway from Outperform to Mkt Perform
Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00
HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously
HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $14.00 from $17.00 previously
HC Wainwright & Co. initiated coverage of BrainsWay with a rating of Buy and set a new price target of $17.00
Northland Capital initiated coverage of Brainsway with a rating of Outperform and set a new price target of $15.00
Oppenheimer reiterated coverage of Brainsway with a rating of Outperform and set a new price target of $15.00 from $13.00 previously
Raymond James reiterated coverage of Brainsway with a rating of Outperform and set a new price target of $12.00 from $9.00 previously
Fastest customizable press release news feed in the world
BURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has completed a $1 million milestone-based investment in Axis Management Company, Inc. ("Axis Integrated Mental Health" or "Axis"), a management services organization servicing several mental health clinics in Colorado. The investment was made following Axis's achievement of a predefined revenue performance milestone under the terms of the two companies' August 2025 strategic equity financing agreement. "We are excited for the Axis tea
Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth) Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIR
GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially f
BURLINGTON, Mass. and JERUSALEM, March 04, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled new clinical data showing a significantly faster, noninvasive way to treat depression without compromising the efficacy of one of psychiatry's most impactful treatments. The milestone advances BrainsWay's brain health vision and sets the stage for a neuromodulation platform that transforms lives. Two new peer-reviewed manuscripts in Brain Stimulation found that BrainsWay's exclusive FDA-cleared SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for the treatment of Major Depressive Disorder (MDD) achieved comparable remission and response rates when
BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, March 11, 2026Time:8:30 AM Eastern TimeUnited States:1-877-300-8521Internationa
BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY. Please contact your Citi representative to request a meeting at the conference. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimu
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health Inc. ("BrainStim"), a provider based in British Columbia servicing a growing number of mental health clinics in Canada. Under the terms of the agreement, BrainsWay will invest $1.0 million initial
BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent news issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magnetic stimulation (TMS) for contracted providers whose patients have coverage under Evernorth and Cigna Healthcare® plans. The Evernorth press release stated that the change will be effective on March 6, 2026. "Evernorth's decision to eliminate
BURLINGTON, Mass. and JERUSALEM, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that its Board of Directors approved a plan to change to the ratio of its American Depositary Shares (ADSs) listed on the Nasdaq Capital Market ("NASDAQ") relative to its ordinary shares traded on the Tel Aviv Stock Exchange. The Company's Board of Directors believes that aligning the ADS ratio with the ordinary share will simplify the Company's capital structure and provide investors with a clearer basis for assessing the Company's valuation. The Company will adjust i
BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for Neurolief's Proliv™Rx system, a Class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder (MDD) who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic. This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-
Live finance-specific insights
Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth) Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIR
BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, March 11, 2026Time:8:30 AM Eastern TimeUnited States:1-877-300-8521Internationa
Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatm
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 11, 2025Time:8:30 AM Eastern TimeUnited States:1-8
BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ("Axis Integrated Mental Health" or "Axis"), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually c
Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported second quarter 2025 financial results and provided an operational update. Recent Financial and
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, August 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300-85
Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net number of Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Company is reiterating its full-year 2025 financial guidance, including revenue of $49 to $51 million, operating profit of 3% to 4% and Adjusted EBITDA of 11% to 12% Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 13, 2025 (GLOBE NEWSWIRE) --
BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300
Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua
This live feed shows all institutional transactions in real time.
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13D - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
SC 13G/A - Brainsway Ltd. (0001505065) (Subject)
Live Leadership Updates
MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more
BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys
Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities. "We are thrilled to welcome Ido and his extensive financial expertise to BrainsWay," stated Hadar Levy, BrainsWay's Chief Executive Officer. "He has led the financial strategy and i
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Hadar Levy, the Company's Senior Vice President (SVP) and Chief Operating Officer (COO), and a member of BrainsWay's senior leadership team since 2014, as Chief Executive Officer (CEO). Mr. Levy has been instrumental as a sales, financial and operational leader for the Company throughout his tenure at BrainsWay, previously serving as the Company's Chief Financial Officer and then General Manager North America, before assuming
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ami Boehm, as Chairman of the Board. David Zacut, M.D., co-founder of BrainsWay, who has held the role of Chairman since the Company's inception, will now serve as a Director on the Board. "It has been very satisfying to have supported BrainsWay's evolution from a nascent R&D start-up to a world-class commercial company offering the industry's leading TMS technology and solution," stated Dr. Zacut. "After 19 intensive years,
BURLINGTON, Mass. and JERUSALEM, Nov. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Colleen A. Hanlon, Ph.D. as Vice President of Medical Affairs. Formerly a professor at Wake Forest University School of Medicine and a member of the Wake Forest Center for Addiction Research, Dr. Hanlon brings nearly 20 years of experience in the field of brain imaging and brain stimulation research. At BrainsWay, she will drive the integration of medical and scientific intelligence to inform TMS providers on state-of-the art
BURLINGTON, Mass. and JERUSALEM, May 09, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Eric Hirt as Vice President of U.S. Sales. Mr. Hirt has more than 20 years of experience in the medical device industry. He will be responsible for all U.S. sales and marketing activities for the Company's Deep Transcranial Magnetic Stimulation (Deep TMS™) system. "Eric brings more than 20 years of experience in medical device sales and marketing to BrainsWay. He has successfully created and implemented sales and marketing str
BURLINGTON, Mass. and JERUSALEM, March 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Joachim "Joe" Seidel, Ph.D., to the newly created position of Vice President of Corporate Development and Strategy. Dr. Seidel has more than 20 years of experience in the medical device industry and has held positions in business development, corporate strategy, program management, and research and development. He will be responsible for pursuing strategic opportunities for BrainsWay and overseeing its global corporate develo
CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer effective today. "We are very pleased to announce that Scott Areglado has joined BrainsWay to become our Senior Vice President and Chief Financial Officer," stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. "Scott's appointment comes at a critically important time for our company, as we expand our commercial operation